<ENAMEX TYPE="ORGANIZATION">Cetus Corp.</ENAMEX> said the government of <ENAMEX TYPE="LOCATION">Spain</ENAMEX> approved the marketing of its <ENAMEX TYPE="ORGANIZATION">Proleukin</ENAMEX> interleukin-2 drug to treat kidney cancer.
The biotechnology concern said Spanish authorities must still clear the price for the treatment, but that it expects to receive such approval by year end. Four other countries in <ENAMEX TYPE="LOCATION">Europe</ENAMEX> have approved Proleukin in recent months. <ENAMEX TYPE="ORGANIZATION">Cetus</ENAMEX> is currently trying to obtain federal regulatory clearance for U.S. distribution.
